Cascader

Based in the UK, Cascader, operates as a a provider of eye diseases and preventive healthcare services and solutions. Founded in 2025, Cascader is based in the UK and specializes in eye care solutions. The funding will support the company's growth and further development of its tools for macular diseases. Cascader specializes in AI-powered solutions focused on enhancing eyecare and providing deeper health insights.

Their flagship products leverage advanced artificial intelligence to optimize clinical workflows and support evidence-based decision-making in high-risk eye conditions, including age-related macular degeneration (AMD). The products are designed for hospitals, primary care providers, and clinicians, primarily serving the UK market and extending to other regions with advanced healthcare systems. Cascader operates on a transaction structure involving partnerships and direct sales within the healthcare sector. The company engages in strategic collaborations with healthcare institutions and offers subscription-based services to clinicians and hospitals, allowing seamless access to AI-driven diagnostic tools.

Revenue generation is tied to the sale of proprietary software related to ocular diseases and preventative health assessments, with customers operating under contractual agreements that specify service deliverables and support provisions. The company plans to utilize the recent funding to support its growth and further develop its tools for macular diseases.